Medtronic (MDT) Competitors

Bristol-Myers Squibb (NYSE:BMY) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Which has higher valuation & earnings, BMY or MDT?

Bristol-Myers Squibb has higher revenue and earnings than Medtronic. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol-Myers Squibb	$46.16B	2.22	$6.33B	$3.94	12.77
Medtronic	$31.23B	3.38	$3.76B	$3.07	25.85

Does the media favor BMY or MDT?

In the previous week, Bristol-Myers Squibb had 4 more articles in the media than Medtronic. MarketBeat recorded 24 mentions for Bristol-Myers Squibb and 20 mentions for Medtronic. Medtronic's average media sentiment score of 0.89 beat Bristol-Myers Squibb's score of 0.68 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol-Myers Squibb	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Medtronic	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in BMY or MDT?

75.0% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 80.8% of Medtronic shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor BMY or MDT?

Medtronic received 505 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. Likewise, 76.70% of users gave Medtronic an outperform vote while only 67.08% of users gave Bristol-Myers Squibb an outperform vote.

Company	Underperform	Outperform
Bristol-Myers Squibb	Outperform Votes 1072 67.08%	Underperform Votes 526 32.92%
Medtronic	Outperform Votes 1577 76.70%	Underperform Votes 479 23.30%

Is BMY or MDT more profitable?

Bristol-Myers Squibb has a net margin of 18.44% compared to Bristol-Myers Squibb's net margin of 12.83%. Medtronic's return on equity of 51.59% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol-Myers Squibb	18.44%	51.59%	17.03%
Medtronic	12.83%	13.73%	7.74%

Do analysts prefer BMY or MDT?

Bristol-Myers Squibb presently has a consensus target price of $63.59, indicating a potential upside of 26.39%. Medtronic has a consensus target price of $93.33, indicating a potential upside of 17.62%. Given Medtronic's higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol-Myers Squibb	1 Sell rating(s)	13 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.17
Medtronic	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Is BMY or MDT a better dividend stock?

Bristol-Myers Squibb pays an annual dividend of $2.28 per share and has a dividend yield of 4.5%. Medtronic pays an annual dividend of $2.76 per share and has a dividend yield of 3.5%. Bristol-Myers Squibb pays out 57.9% of its earnings in the form of a dividend. Medtronic pays out 89.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb has raised its dividend for 14 consecutive years and Medtronic has raised its dividend for 47 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Which has more risk & volatility, BMY or MDT?

Bristol-Myers Squibb has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Medtronic on 11 of the 21 factors compared between the two stocks.